Home › Compare › BOREF vs ABBV
BOREF yields 100.00% · ABBV yields 3.06%● Live data
📍 BOREF pulled ahead of the other in Year 1
Combined, BOREF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOREF + ABBV for your $10,000?
Borealis Exploration Limited, a technology development company, engages in inventing, patenting, developing, and acquiring new technologies. Its principal technologies include Chorus Meshcon, an electric motor/drive providing high torque at low speeds without compromising high-speed operation and performance; WheelTug, an aircraft electric drive system, which enables ircraft to drive forward and backward without using its engines or external tugs; Avto Metals, a custom-designed material for applications in microelectronic devices, including computers, cell phones, and multifunction digital tools. The company's principal technologies also include Cool Chips, which are devices that use quantum electron thermotunnelling to produce cooling, refrigeration, or air-conditioning, which has applications in cooling electronics, refrigerators and freezers, medical and industrial equipment, buildings, cargo, aircraft, and cars; and Power Chips, a new technology that uses the physical mechanism of thermionics and quantum thermotunnelling to generate electrical power directly from heat, with no moving parts, produce power for laptop computers, buildings, and cars and trucks. It also holds interests in various iron ore deposits. The company was founded in 1965 and is headquartered in Gibraltar, Gibraltar.
Full BOREF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.